Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients

Spahn, Martin; Joniau, Steven; Gontero, Paolo; Fieuws, Steffen; Marchioro, G.; Tombal, Bertrand; Kneitz, Burkhard; Hsu, Chao‐Yu; Eeckt, Katie Van Der; Bader, Pia; Frohneberg, D.; Tizzani, A; Poppel, Hendrik Van

doi:10.1016/j.eururo.2010.03.001

Cited by 141 publications

(78 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men classified as having high risk PCa are known to be a highly heterogenous group in terms of surgical resectability and outcomes [116][117][118], some of whom are curable by radical prostatectomy and others of whom are not curable by surgery and would benefit more from combined androgen deprivation and radiotherapy. It is possible that routine MRI in higher-risk men may identify those with evidence of extensive T3 disease, whom are inappropriate for radical prostatectomy.…”

Section: Mri In T-staging Treatment Selection and Planningmentioning

confidence: 99%

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

et al. 2013

View full text Add to dashboard Cite

Background• The diagnosis of prostate cancer has long been plagued by the absence of an imaging tool that reliably detects and localises significant tumours. Recent evidence suggests that multi-parametric MRI could improve the accuracy of diagnostic assessment in prostate cancer. This review serves as a background to a recent USANZ position statement. It aims to provide an overview of MRI techniques and to critically review the published literature on the clinical application of MRI in prostate cancer. Technical Aspects• The combination of anatomical (T2-weighted) MRI with at least two of the three functional MRI parameterswhich include diffusion-weighted imaging, dynamic contrast-enhanced imaging and spectroscopy -will detect greater than 90% of significant (moderate to high risk) tumours; however MRI is less reliable at detecting tumours that are small (<0.5 cc), low grade (Gleason score 6) or in the transitional zone. The higher anatomical resolution provided by 3-Tesla magnets and endorectal coils may improve the accuracy, particularly in primary tumour staging.

show abstract

Section: Mri In T-staging Treatment Selection and Planningmentioning

confidence: 99%

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Consecutive men with high-risk prostate cancer [prostatespecific antigen (PSA) >20 ng/mL and/or clinical stage T3/4 and/or biopsy Gleason score [8][9][10], who had undergone radical prostatectomy between 1987 and 2005 at the Community Hospital of Karlsruhe, Germany (cohort 1) and the University Hospital Leuven, Belgium (cohort 2), were identified in the European Clinical and Translational High-Risk Prostate Cancer Research Groupdatabase (EMPaCT) andwereincluded intothis study. Clinical stage was assigned according to the 2002 TNM system, prostate biopsy cores were obtained under transrectalultrasound guidance, and pretreatment PSA was measured before digital rectal examination (DRE) or prostate ultrasound.…”

Section: Patients and Samplesmentioning

confidence: 99%

“…5). Up to 30% of these men will develop metastasis and finally die of their disease (6)(7)(8). Based on these relatively high event rates, if compared with low-/intermediate-risk study groups, high-risk prostate cancer represents a good cohort to validate preexisting biomarkers predicting clinical failure and cancer-related death (CRD).…”

Section: Introductionmentioning

confidence: 99%

Survival in Patients with High-Risk Prostate Cancer Is Predicted by miR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3

Kneitz¹,

Krebs²,

Kalogirou³

et al. 2014

Cancer Research

Self Cite

108

View full text Add to dashboard Cite

A lack of reliably informative biomarkers to distinguish indolent and lethal prostate cancer is one reason this disease is overtreated. miR-221 has been suggested as a biomarker in high-risk prostate cancer, but there is insufficient evidence of its potential utility. Here we report that miR-221 is an independent predictor for cancerrelated death, extending and validating earlier findings. By mechanistic investigations we showed that miR-221 regulates cell growth, invasiveness, and apoptosis in prostate cancer at least partially via STAT1/STAT3-mediated activation of the JAK/STAT signaling pathway. miR-221 directly inhibits the expression of SOCS3 and IRF2, two oncogenes that negatively regulate this signaling pathway. miR-221 expression sensitized prostate cancer cells for IFN-g-mediated growth inhibition. Our findings suggest that miR-221 offers a novel prognostic biomarker and therapeutic target in high-risk prostate cancer. Cancer Res; 74(9); 2591-603. Ó2014 AACR.

show abstract

“…The inclusion of biopsy-derived information is very important when predicting LNI due to the predictive value of percentage positive cores for nodal metastases [Briganti et al 2012]. While acknowledging that the use of lymphadenectomy in PCa is a controversial point [Briganti et al 2009a[Briganti et al , 2009bMiki and Egawa, 2011;Spahn et al 2010], some believe that lymphadenectomy can be curative. However, more data are needed to confirm this belief.…”

Section: Identifying Individualizing and Improving Patient Carementioning

confidence: 99%

Controversies on individualized prostate cancer care: gaps in current practice

Joniau¹,

Pfister

Taille

et al. 2013

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCa) is a heterogeneous disease with a wide spectrum of aggressiveness. Evidence-based guidelines are invaluable but cannot be expected to be extensive enough to provide detailed guidance on the management of all patients. As such, the use of individualized, risk-adapted approaches to the management of PCa is indispensable. However, wide variation in treatment approaches observed for patients in practice suggests that there is an unmet need to improve the individualized approach towards patient care. A holistic approach that encompasses guidelines and evidence-based medicine could be used to guide individualized care for patients with PCa, from first contact through to final outcomes. As a result of an international expert meeting, this paper proposes this approach and highlights some of the factors that can be considered when aiming to identify patients' profiles; individualize treatment; and improve communication between patients and the healthcare teams.

show abstract

Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients

Cited by 141 publications

References 23 publications

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

Survival in Patients with High-Risk Prostate Cancer Is Predicted by miR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3

Controversies on individualized prostate cancer care: gaps in current practice

Contact Info

Product

Resources

About